PMID- 27569975
OWN - NLM
STAT- MEDLINE
DCOM- 20170428
LR  - 20181202
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 48
IP  - 6
DP  - 2016 Jul-Aug
TI  - Prediction of Complement-Binding Capacity of HLA Antibodies Based on Mean 
      Fluorescence Intensity.
PG  - 2235-40
LID - S0041-1345(16)30178-6 [pii]
LID - 10.1016/j.transproceed.2016.04.018 [doi]
AB  - BACKGROUND: Human leukocyte antigen (HLA) antibodies estimated by Luminex 
      single-antigen beads, especially those that fix complement, are associated with 
      antibody-mediated rejection and graft failure. However, the relationship between 
      HLA antibody strength and complement-binding ability is controversial. METHODS: 
      Serum samples of 31 sensitized renal patients waiting for renal transplantation 
      were retrospectively analyzed by IgG-Luminex to identify HLA antibodies and in 
      parallel by C1q-Luminex to determine the complement binding of HLA antibodies. 
      RESULTS: The percentage of HLA class I antibodies binding with C1q was lower than 
      that of HLA class II antibodies (43.2% vs. 51.3%, P = .006). The mean 
      fluorescence intensities (MFI) of IgG-Luminex correlated with the MFI of 
      C1q-Luminex for the same antibodies (Spearman correlation; class I, r = 0.665, 
      P < .01; class II, r = 0.761, P < .01). Receiver operating characteristic (ROC) 
      curve analysis showed that the MFIs of HLA antibodies by IgG-Luminex predicted 
      their C1q-binding abilities (area under the curve [AUC] class I = 0.917; AUC 
      class II = 0.927). Using MFI cutoff values of 8238 and 6754 in IgG-Luminex for 
      HLA class I and class II antibodies, respectively, the sensitivity and 
      specificity for C1q binding were 82.4% and 87.4% for class I antibodies and 90.9% 
      and 82% for class II antibodies. CONCLUSIONS: The MFI of HLA antibodies by 
      IgG-Luminex predicts the complement-binding capability to a certain extent before 
      transplantation.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Zhao, J
AU  - Zhao J
AD  - Department of Urology, The Second Hospital of Tianjin Medical University, 
      Tianjin, China; Department of Transplant Surgery, Tianjin First Central Hospital, 
      Tianjin, China.
FAU - Fu, Y X
AU  - Fu YX
AD  - Department of Transplant Surgery, Tianjin First Central Hospital, Tianjin, China.
FAU - Yang, T
AU  - Yang T
AD  - Department of Transplant Surgery, Tianjin First Central Hospital, Tianjin, China.
FAU - Shen, Z Y
AU  - Shen ZY
AD  - Department of Transplant Surgery, Tianjin First Central Hospital, Tianjin, China.
FAU - Wu, C L
AU  - Wu CL
AD  - Department of Urology, The Second Hospital of Tianjin Medical University, 
      Tianjin, China. Electronic address: changliwu2014@aliyun.com.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
RN  - 0 (Antibodies)
RN  - 0 (HLA Antigens)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Immunoglobulin G)
RN  - 80295-33-6 (Complement C1q)
SB  - IM
MH  - Adult
MH  - Antibodies/blood/*immunology
MH  - Complement C1q/immunology
MH  - Complement Fixation Tests
MH  - Female
MH  - Fluorescence
MH  - Fluorescent Antibody Technique/methods
MH  - Graft Rejection/immunology
MH  - HLA Antigens/blood/*immunology
MH  - Histocompatibility Antigens Class I/immunology
MH  - Humans
MH  - Immunoglobulin G/immunology
MH  - Kidney Failure, Chronic/blood/*immunology/surgery
MH  - Kidney Transplantation
MH  - Male
MH  - Middle Aged
MH  - Predictive Value of Tests
MH  - ROC Curve
MH  - Reference Values
MH  - Retrospective Studies
MH  - Sensitivity and Specificity
MH  - Waiting Lists
EDAT- 2016/08/30 06:00
MHDA- 2017/04/30 06:00
CRDT- 2016/08/30 06:00
PHST- 2016/01/24 00:00 [received]
PHST- 2016/03/23 00:00 [revised]
PHST- 2016/04/07 00:00 [accepted]
PHST- 2016/08/30 06:00 [entrez]
PHST- 2016/08/30 06:00 [pubmed]
PHST- 2017/04/30 06:00 [medline]
AID - S0041-1345(16)30178-6 [pii]
AID - 10.1016/j.transproceed.2016.04.018 [doi]
PST - ppublish
SO  - Transplant Proc. 2016 Jul-Aug;48(6):2235-40. doi: 
      10.1016/j.transproceed.2016.04.018.